Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls

References

• Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(Suppl 6):11–20.
   PubMed Web of Science ®Google Scholar
• Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511–25.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, . Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4–12.
   PubMed Web of Science ®Google Scholar
• Ukkola O. Ghrelin and metabolic disorders. Curr Protein Pept Sci 2009;10:2–7.
   PubMedGoogle Scholar
• Yan E, Chen S, Hong K, Kim WS, Bajpai A, Treyzon L, . Insulin, hs-CRP, leptin, and adiponectin. An analysis of their relationship to the metabolic syndrome in an obese population with an elevated waist circumference. Metab Syndr Relat Disord 2008;6:64–73.
   PubMedGoogle Scholar
• Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456–9.
   PubMed Web of Science ®Google Scholar
• Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1–4.
   PubMed Web of Science ®Google Scholar
• Elman I, Goldstein DS, Green AI, Eisenhofer G, Folio CJ, Holmes CS, . Effects of risperidone on the peripheral noradrenergic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology 2002;27:293–300.
   PubMedGoogle Scholar
• Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3–16.
   PubMed Web of Science ®Google Scholar
• Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001;62(Suppl 7):4–10.
   PubMedGoogle Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, . H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519–26.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain – mechanisms and genetics. J Psychopharmacol 2006;20(Suppl):15–8.
   PubMedGoogle Scholar
• Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust NZ J Psychiatry. 2008;42:369–81.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 2004;101:10434–9.
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930–5.
   PubMed Web of Science ®Google Scholar
• Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21–34.
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, . Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009;194:434–8.
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008;100:70–85.
   PubMed Web of Science ®Google Scholar
• Havel PJ. Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Exp Biol Med 2001;226:963–77.
   PubMed Web of Science ®Google Scholar
• Vázquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 2008;39:715–28.
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, . Weight reducing effects of the plasma protein encoded by the obese gene. Science 1995;269: 543–6.
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269: 540–3.
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996;98:1101–6.
   PubMed Web of Science ®Google Scholar
• Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 1996;334:292.
   PubMed Web of Science ®Google Scholar
• Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006;89: 71–84.
   PubMed Web of Science ®Google Scholar
• Tschöp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Folwaczny C. Postprandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001;24:RC19–21.
   PubMed Web of Science ®Google Scholar
• Zigman JM, Elmquist JK. Minireview: From anorexia to obesity – the yin and yang of body weight control. Endocrinology 2003;144:3749–56.
   PubMed Web of Science ®Google Scholar
• Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194–8.
   PubMed Web of Science ®Google Scholar
• Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, . Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227–32.
   PubMed Web of Science ®Google Scholar
• Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2004;24:225–53.
   Web of Science ®Google Scholar
• Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, . Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001;145:669–73.
   PubMed Web of Science ®Google Scholar
• Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002;56:203–6.
   PubMed Web of Science ®Google Scholar
• Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Ranchelli A, . Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. J Endocrinol Invest 2004;27:RC12–5.
   PubMedGoogle Scholar
• Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271;10697–703.
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.
   PubMed Web of Science ®Google Scholar
• Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, . Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55–68.
   PubMed Web of Science ®Google Scholar
• Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147:173–80.
   PubMed Web of Science ®Google Scholar
• Sentissi O, Epelbaum J, Olié JP, Poirier MF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008;34:1189–99.
   PubMed Web of Science ®Google Scholar
• Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005;30:184–91.
   PubMed Web of Science ®Google Scholar
• Esen-Danaci A, Sarandöl A, Taneli F, Yurtsever F, Ozlen N. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1434–8.
   PubMedGoogle Scholar
• Herrán A, García-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vázquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001;179:59–62.
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses – a comparison between different antipsychotic agents. Psychopharmacology 2001;154:205–12.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Zhang ZJ, Sun J, Zhang XB, Mou XD, Zhang XR, . Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 2006;15;60:1309–13.
   Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003;18:457–61.
   PubMed Web of Science ®Google Scholar
• Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010;118:218–23.
   PubMed Web of Science ®Google Scholar
• Hauner H, Röhrig K, Hebebrand J, Skurk T. No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors. Mol Psychiatry 2003;8:258–9.
   PubMedGoogle Scholar
• Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M, . Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berlin) 2004;172:230–2.
   PubMedGoogle Scholar
• Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, . Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007;85:249–56.
   PubMed Web of Science ®Google Scholar
• Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A. preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001;50:1714–9.
   PubMed Web of Science ®Google Scholar
• Murashita M, Inoue T, Kusumi I, Nakagawa S, Itoh K, Tanaka T, . Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007;61:54–8.
   PubMed Web of Science ®Google Scholar
• Hanssens L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Reginster JY, . A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008;106:308–14.
   PubMed Web of Science ®Google Scholar
• Togo T, Kojima K, Shoji M, Kase A, Uchikado H, Katsuse O, . Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004;19:37–40.
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, . Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res. 2009;111:1–8.
   PubMed Web of Science ®Google Scholar
• Oriot P, Feys JL, Mertens de Wilmars S, Misson A, Ayache L, Fagnart O, . Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab 2008;34:490–6.
   PubMedGoogle Scholar